SciSparc Ltd. · NASDAQ:SPRC
SciSparc — Investor Presentation (February 2021)
23 slides from SciSparc's investor presentation, February 2021
Slide 1: SciSparc Corporate Presentation February 2021
SciSparc Corporate Presentation February 2021 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation of SciSparc Ltd. (the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” an
Slide 3: Our Vision
Our Vision To bridge cannabis and cannabinoids to the healthcare system to improve the health and wellbeing of patients 3
Slide 4: SciSparc Company Highlights
SciSparc Company Highlights • Developing cannabinoid-based therapies • Science driven and targeted treatment solutions • New, committed experienced managment • Entourage Effect seeks to increase efficiency, lower dosage and side effects • Our intellectual property portfolio comprises three granted U
Slide 5: The SciSparc Story
A specialty pharmaceutical company The SciSparc Story focused on repurposing approved cannabinoids for new indications Platform Programs SCI- SCI- SCI- 110 160 210 An innovative and proprietary drug candidate platform based on U.S. Food An innovative proprietary drug An innovative and and Drug Admin
Slide 6: The Entourage Effect
The“EntourageEffect” The "Entourage Effect", first described by Prof. Raphael Mechoulam in 1998* Effects of the Endocannabinoid The Entourage technology is the system can be explained by its basis of all the therapeutic drugs overall constituents working we are developing together, synergistically,
Slide 7: SciSparc Platform
SciSparc Platform Seeking to Increase Efficiency, Lower Dosage and Fewer Side Effects “The Entourage Effect“ SciSparc’s proprietary combination of CannAmideTM and any Cannabinoid creating an “Entourage Effect”, first discovered by Prof. Raphael Mechoulam in 1998, which results in synergy. CannAmideT
Slide 8: SciSparc Platform: Harnessing the Entourage Effect Phenomenon
SciSparc Platform: Harnessing the Entourage EffectPhenomenon Seeking to Improve Efficacy and Minimize Psychological Side Effects Dose Matters Dosage regiment may compromise therapeutic benefits of cannabis and mayseverely impact treatment • Serious diminishing effect over time and extensive use • Hi
Slide 9: Tourette Syndrome (TS)
Tourette Syndrome (TS) Disease Overview & Clinical Features Disease Overview • TS is a movement and neurobehavioral disorder characterized by motor and vocal chronic tics with onset before age 18 • About half to two-thirds of the cases get much better during adolescence1 • However, adults will gener
Slide 10: TS Phase IIa Clinical Trial
TS Phase IIa Clinical Trial SCI-110: Seeking to Provide Increased Efficiency, Lower Dosage and Fewer Side Effects TS is a movement and neurobehavioral disorder characterized by motor and vocal tics and is highly linked with co-morbidities We believe that topline results from our trial conducted in Y
Slide 11: TS Phase IIb Clinical Trial
TS Phase IIb Clinical Trial SCI-110: Seeking to Provide Increased Efficiency, Lower Dosage and Fewer Side Effects • SciSparc intends to evaluate the efficacy, safety and tolerability of its SCI-110 in a randomized, double-blind, placebo controlled, cross-over study • The study is expected to commenc
Slide 12: SCI-110 for Obstructive Sleep Apnea (OSA)
SCI-110 for Obstructive Sleep Apnea (OSA) Seeking to Provide Increased Efficiency, Lower Dosage and Side Effects OSA causes breathing to repeatedly stop during sleep and is a potentially lethal sleep disorder. There are currently no FDA approved pharmaceutical therapies to treat this disorder1 1http
Slide 13: OSA Phase IIa Clinical Trial
OSA Phase IIa Clinical Trial We Believe that Topline Results from our Trial Conducted in Assuta Sleep Clinic in 2019 Show Encouraging Results: • Of the 10 patients recruited into the study, nine patients have completed the study and one has dropped out of the study due to treatment associated advers
Slide 14: SCI-110 for Alzheimer’s Disease and Agitation
SCI-110 for Alzheimer’s Disease and Agitation Seeking to Provide Increased Efficiency, Lower Dosage and Fewer Side Effects • Dementia is a clinical syndrome characterized by progressive decline in two or more cognitive domains, including memory, language, executive and visuospatial function, persona
Slide 15: SCI-210 for Autism Spectrum Disorder (ASD)
SCI-210 for Autism Spectrum Disorder (ASD) Autism: A Rapidly Growing Population with Array of Symptoms PEA Significantly Increases CBD Effects1 CBD was shown to prevent fat accumulation in liver cells in a concentration dependent manner PEA by itself didn’t affect fat accumulation Addition of PEA to
Slide 16: SCI-160 for Pain
SCI-160 for Pain • An innovative and proprietary CB2 Receptor Agonist formulation intended for the treatment of pain. This specific CB2 receptor agonist was synthesized by Professor Raphael Mechoulam, Ph.D. • SCI-160, a synthetic CB2 Receptor Agonist, which is protected under a patent granted in the
Slide 17: CannAmide™
CannAmide™ CannAmideTM (TheraPEA) – For pain and inflammation: • Active ingredient Palmitoylethanolamide– Advantages over other PEA products ✓CannAmide is a special formulation designed to increase PEA solubility and absorption as opposed to most if not all PEA products available as yet on the marke
Slide 18: CannAmide™
CannAmide™ CannAmideTM (TheraPEA) – For pain and inflammation: • Active ingredient Palmitoylethanolamide– • Endocannabinoid-like compound, a lipid-messenger and an endogenous neuromodulator with a broad spectrum of pharmacological properties and can be found naturally in the body, as well as in egg
Slide 19: Pipeline
Pipeline COMPOUND THERAPEUTIC AREA PRECLINICAL Medical Cannabis PHASE IIa PHASE IIb route CannAmide™ ANTI-INFLAMMATORY TO HELP RELIEVE CHRONIC PAIN (COMMERCIAL) TOURETTE SYNDROME SCI – 110 OBSTRUCTIVE SLEEP APNEA SCI– 110 SCI– 110 ALZHEIMER DISEASE AND AGITATION AUTISM SCI – 210 PAIN SCI– 160 SCI-11
Slide 20: Highlights
Highlights • We believe that we have unique technologies in the medical cannabis market • Focus on cannabinoid family products with unique and proprietary combinations, methods of administrations and formulations • Pursuing new high potential R&D and clinical programs • Advanced clinical programs •
Slide 21: SciSparc’s Management
SciSparc’s Management Amitai Weiss, CEO Mr. Weiss currently serves as chairman of the board of directors of P.L.T Financial Services Ltd., as chairman of the board of directors of Matomy Media Group Ltd. and as an external director of Cofix Group Ltd. In 2016, Mr. Weiss founded Amitay Weiss Manageme
Slide 22: SciSparc’s Board of Directors
SciSparc’s Board of Directors Mr. Itschak Shrem, Chairman of the Board Lior Amit, Director Moshe Revach, Director Mr. Shrem has more than 40 years of experience in Mr. Amit serves as a consultant to both private and Mr. Revach serves as deputy mayor of the city of financial markets and venture capit
Slide 23: SciSparc Scientific Advisory Board
SciSparc Scientific Advisory Board Award winning, active scientists Dr. Michael Bloch Prof. Elon Eisenberg Prof. James Leckman CNS Prof. Michael Davidson Pain Prof. Avi Weizman Dr. Daniele Piomelli Prof. Raphael Mechoulam Prof. David Nutt Prof. Kirsten Muller-Vahl Prof. Saoirse. O'Sullivan Dr. Josep